Heart Valve, Spine Markets To Drive Device Growth After DES – CMS Report
This article was originally published in The Gray Sheet
Executive Summary
Percutaneous heart valve repair and replacement likely will drive the next wave of medical device industry expansion as cardiac resynchronization therapy (CRT) and drug-eluting stent innovations plateau, a CMS report speculates
You may also be interested in...
FDA Review Criteria Are Insufficient To Prompt CMS Coverage – Feigal, Tunis
Proposals allowing FDA's approval criteria to play a greater role in Medicare coverage determinations should account for the fact that many devices are cleared via 510(k) and not reviewed for clinical effectiveness, CDRH Director David Feigal asserted Oct. 11
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.